Navigation Links
Best Antidepressant May Depend on Patient: Study
Date:12/6/2011

By Amanda Gardner
HealthDay Reporter

MONDAY, Dec. 5 (HealthDay News) -- Newer antidepressants seem to be about as effective as one another, a new analysis indicates.

This suggests that the choice of which drug is appropriate for which patient should be made on the basis of such considerations as side effects, cost and patient preference.

"They're all equally effective," said Dr. David Schlager, a clinical assistant professor of psychiatry and behavioral science at Texas A&M Health Science Center College of Medicine.

"They're interchangeable except for side effects," he added, so psychiatrists do tend to "exploit the side-effect profile" to find suitable medications for individual patients, he added.

According to the background information in the new study, appearing in the Dec. 6 issue of Annals of Internal Medicine, some 27 million people in the United States had taken antidepressants as of 2005.

Most of these drugs are "second-generation" medications such as selective serotonin reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors (SNRIs) and related drugs.

SSRIs include the best-selling Prozac (fluoxetine) and Zoloft (sertraline). An example of an SNRI is Effexor (venlafaxine).

Led by Dr. Gerald Gartlehner, the analysis was funded primarily by the U.S. Agency for Healthcare Research and Quality.

Authors reviewed data from 234 previously published studies, all of them randomized trials that had included at least 1,000 participants each.

While there was no difference in drug effectiveness, there were distinctions in how quickly a drug took effect, side effects and quality of life.

For instance, the authors said, Remeron (mirtazapine) takes effect faster than Prozac, Zoloft, Paxil (paroxetine) or Celexa (citalopram).

Bupropion, which goes by Wellbutrin and other brand names, has fewer adverse sexual effects than Prozac, Zoloft, Paxil or Lexapro (escitalopram).

"If a patient has insomnia, you would pick something more immediately sedating," said Schlager, who is also a psychiatrist with Lone Star Circle of Care in Austin. "If the patient has decreased appetite and weight loss, you would pick something more likely to cause weight gain like mirtazapine."

Cost, of course, is another consideration.

"If one drug costs $200 a month and another costs $20, I don't see any reason why not to go with the latter," said Dr. Radu Saveanu, a professor of psychiatry at the University of Miami Miller School of Medicine.

Dosing is also important, he said, "because studies have shown that if patients have to take the drug less frequently, compliance is higher, which will make a big difference in terms of efficacy."

But given the similarity in effectiveness, prescribing antidepressants is still largely a trial-and-error process.

It's hoped that the next series of studies will provide guidance on which medications to try first.

"The real heart of the matter is, if they don't respond to one type of antidepressant, is there any guidelines about what you should try next?" Schlager said.

More information

The U.S. National Library of Medicine has more on antidepressants.

SOURCES: Radu V. Saveanu, M.D., professor, psychiatry, University of Miami Miller School of Medicine; David Schlager, M.D., clinical assistant professor, psychiatry and behavioral science, Texas A&M Health Science Center College of Medicine, and psychiatrist, Lone Star Circle of Care, Austin; Dec. 6, 2011, Annals of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antidepressant linked to developmental brain abnormalities in rodents
2. Antidepressant Use Skyrocketed in Past 20 Years: CDC
3. Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients
4. Screen finds an antidepressant and other drugs
5. Fear of Antidepressants Keep Many From Disclosing Depression
6. Antidepressant Tied to Dangerous Heart Rhythm: FDA
7. Antidepressant Tied to Dangerous Heart Rhythm, FDA Says
8. Americans Use of Antidepressants On the Rise: Study
9. Certain Antidepressants Linked to Falls in Nursing Homes
10. Two Antidepressants Given to Dementia Patients Ineffective: Study
11. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Best Antidepressant May Depend on Patient: Study
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: